These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17752015)

  • 1. Continuously Cultured Tissue Cells and Viral Vaccines: Potential advantages may be realized and potential hazards obviated by careful planning and monitoring.
    Committee on Tissue Culture Viruses and Vaccines
    Science; 1963 Jan; 139(3549):15-20. PubMed ID: 17752015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a cell line system susceptible to infection with vaccine strains of MDV.
    Abujoub AA; Williams DL; Reilly JD
    Acta Virol; 1999; 43(2-3):186-91. PubMed ID: 10696443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous cell substrate considerations.
    Lubiniecki AS
    Bioprocess Technol; 1990; 10():495-513. PubMed ID: 1370028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonperfused attachment systems for cell cultivation.
    Elliott AY
    Bioprocess Technol; 1990; 10():207-16. PubMed ID: 1367060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing issues of quality control: diploid and non-diploid cell lines.
    Pearson J
    Dev Biol Stand; 1992; 76():13-7. PubMed ID: 1478333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine.
    Tatalick LM; Gerard CJ; Takeya R; Price DN; Thorne BA; Wyatt LM; Anklesaria P
    Vaccine; 2005 Apr; 23(20):2628-38. PubMed ID: 15780446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amended final report on the safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl diricinoleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate, glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate.
    Int J Toxicol; 2007; 26 Suppl 3():1-30. PubMed ID: 18273450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Karyology and tumorigenicity testing requirements: past, present and future.
    Petricciani JC; Horaud FN
    Dev Biol Stand; 1998; 93():5-13. PubMed ID: 9737371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Operator-induced contamination in cell culture systems.
    Hay RJ
    Dev Biol Stand; 1991; 75():193-204. PubMed ID: 1794620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
    Barrett PN; Mundt W; Kistner O; Howard MK
    Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered structure-based vaccine for bluetongue disease.
    Roy P
    Vet Ital; 2004; 40(4):594-600. PubMed ID: 20422594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.